PHOENIX, Feb 25, 2004 (BUSINESS WIRE) -- Vital Living, Inc. (OTC Bulletin Board: VTLV) today announced it has launched X-Fat(R), the Company's liquid dietary supplement that helps prevent fat from entering the bloodstream. The Company is initially marketing X-Fat(R) through a variety of methods, including four major markets by way of radio advertisements (Minneapolis, MN, Houston, TX, Miami, FL, Philadelphia, PA) .
The power behind X-Fat(R) is Kytasorbe(R), a patented liquid form of the natural fat absorber, chitosan. X-Fat(R) is free of ephedra and stimulants.
About Vital Living
Vital Living, http://www.vitalliving.com, develops or licenses nutraceuticals and pharmaceuticals and markets them for distribution through physicians, medical groups, chiropractic offices and other retail outlets. Vital Living develops and tests its nutraceuticals in collaboration with leading medical experts in the nutraceuticals field and has designed them to be incorporated by physicians into a standard physician-patient program in which patients supplement doctor-prescribed pharmaceuticals with its nutraceuticals. Vital Living provides unique, safe, and efficacious naturally derived nutritional products, utilizing advanced drug-delivery technologies, including the Geomatrix(R) technology through its affiliation with SkyePharma PLC. The Geomatrix(R) technology has been provided exclusively for Vital Living's pharmaceutical development in China, and the development of nutraceuticals. The Company's initial areas of focus are cardiovascular health, through its product Essentum(R) which is currently undergoing clinical trials and being endorsed by the Arizona Heart Institute and prescribed throughout the United States, and weight loss, through its product X-Fat, the Company's patented dietary supplement that uses Kytabsorbe, a liquid form of the nature fat absorber, Chitosan. Vital Living also owns MAF BioNutritionals, Dr. Christopher's line of over 300 products and Doctors for Nutrition.
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the Company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company's ability to continue to successfully market and provide its products and services and maintain their effectiveness, the continuation of the arrangements with the Company's product development partners, the ability of the company to meet its financial projections, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.